S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
Log in
NASDAQ:STRO

Sutro Biopharma Stock Forecast, Price & News

$21.11
+0.82 (+4.04 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$19.04
Now: $21.11
$21.24
50-Day Range
$20.29
MA: $24.42
$27.54
52-Week Range
$6.00
Now: $21.11
$28.30
Volume606,083 shs
Average Volume508,676 shs
Market Capitalization$814.93 million
P/E RatioN/A
Dividend YieldN/A
Beta0.8
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Sutro Biopharma logo

Headlines

Sutro Biopharma Inc
October 24, 2020 |  bloomberg.com
Stock Alert: Sutro Biopharma Gains 9%
September 14, 2020 |  nasdaq.com
See More Headlines

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:STRO
CUSIPN/A
CIKN/A
Phone650-392-8412
Employees182
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$42.74 million
Book Value$4.24 per share

Profitability

Net Income$-55,740,000.00

Miscellaneous

Market Cap$814.93 million
Next Earnings Date3/15/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.30 out of 5 stars

Medical Sector

772nd out of 1,969 stocks

Biological Products, Except Diagnostic Industry

108th out of 177 stocks

Analyst Opinion: 2.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$21.11
+0.82 (+4.04 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive STRO News and Ratings via Email

Sign-up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Sutro Biopharma (NASDAQ:STRO) Frequently Asked Questions

Is Sutro Biopharma a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Sutro Biopharma stock.
View analyst ratings for Sutro Biopharma
or view top-rated stocks.

What stocks does MarketBeat like better than Sutro Biopharma?

Wall Street analysts have given Sutro Biopharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Sutro Biopharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Sutro Biopharma?

Sutro Biopharma saw a drop in short interest in January. As of January 29th, there was short interest totaling 916,000 shares, a drop of 19.6% from the January 14th total of 1,140,000 shares. Based on an average trading volume of 648,100 shares, the short-interest ratio is currently 1.4 days.
View Sutro Biopharma's Short Interest
.

When is Sutro Biopharma's next earnings date?

Sutro Biopharma is scheduled to release its next quarterly earnings announcement on Monday, March 15th 2021.
View our earnings forecast for Sutro Biopharma
.

How were Sutro Biopharma's earnings last quarter?

Sutro Biopharma, Inc. (NASDAQ:STRO) announced its quarterly earnings results on Thursday, November, 5th. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.96. The company had revenue of $17.82 million for the quarter, compared to analysts' expectations of $8.71 million. Sutro Biopharma had a net margin of 27.60% and a negative trailing twelve-month return on equity of 41.86%.
View Sutro Biopharma's earnings history
.

How has Sutro Biopharma's stock price been impacted by Coronavirus (COVID-19)?

Sutro Biopharma's stock was trading at $8.11 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, STRO stock has increased by 160.3% and is now trading at $21.11.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for STRO?

7 analysts have issued 12-month price objectives for Sutro Biopharma's stock. Their forecasts range from $17.00 to $37.00. On average, they expect Sutro Biopharma's stock price to reach $23.33 in the next year. This suggests a possible upside of 10.5% from the stock's current price.
View analysts' price targets for Sutro Biopharma
or view top-rated stocks among Wall Street analysts.

Who are Sutro Biopharma's key executives?

Sutro Biopharma's management team includes the following people:
  • Mr. William J. Newell, CEO & Director (Age 63, Pay $719.92k)
  • Dr. Trevor J. Hallam, Chief Scientific Officer (Age 62, Pay $700.48k)
  • Dr. Arturo M. Molina, Chief Medical Officer (Age 62, Pay $616.76k)
  • Dr. Shabbir T. Anik, Chief Technical Operations Officer (Age 68)
  • Dr. James R. Swartz, Founder and Member of Scientific Advisory Board
  • Mr. Edward C. Albini, CFO & Sec. (Age 63)
  • Ms. Annie J. Chang, Head of Investor Relations
  • Ms. Linda A. Fitzpatrick, Chief People & Communications Officer (Age 64)
  • Dr. Nicki Vasquez, Sr. VP of Alliance Management, Portfolio Strategy & Operations
  • Mr. Stephen T. Worsley, Chief Bus. Officer (Age 58)

What is William J. Newell's approval rating as Sutro Biopharma's CEO?

11 employees have rated Sutro Biopharma CEO William J. Newell on Glassdoor.com. William J. Newell has an approval rating of 100% among Sutro Biopharma's employees. This puts William J. Newell in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Sutro Biopharma's key competitors?

What other stocks do shareholders of Sutro Biopharma own?

When did Sutro Biopharma IPO?

(STRO) raised $75 million in an initial public offering on Thursday, September 27th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Sutro Biopharma's stock symbol?

Sutro Biopharma trades on the NASDAQ under the ticker symbol "STRO."

Who are Sutro Biopharma's major shareholders?

Sutro Biopharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.04%), Frazier Management LLC (2.59%), FIL Ltd (1.93%), Avidity Partners Management LP (1.62%), Ikarian Capital LLC (1.59%) and Candriam Luxembourg S.C.A. (0.95%). Company insiders that own Sutro Biopharma stock include Arturo Md Molina, John Gordon Freund, Trevor Hallam and William J Newell.
View institutional ownership trends for Sutro Biopharma
.

Which institutional investors are selling Sutro Biopharma stock?

STRO stock was sold by a variety of institutional investors in the last quarter, including Endurant Capital Management LP, Barclays PLC, JPMorgan Chase & Co., and HighVista Strategies LLC. Company insiders that have sold Sutro Biopharma company stock in the last year include John Gordon Freund, and Trevor Hallam.
View insider buying and selling activity for Sutro Biopharma
or view top insider-selling stocks.

Which institutional investors are buying Sutro Biopharma stock?

STRO stock was bought by a variety of institutional investors in the last quarter, including Frazier Management LLC, BlackRock Inc., Avidity Partners Management LP, FIL Ltd, Candriam Luxembourg S.C.A., Orbimed Advisors LLC, Silverarc Capital Management LLC, and Opaleye Management Inc.. Company insiders that have bought Sutro Biopharma stock in the last two years include Arturo Md Molina, and William J Newell.
View insider buying and selling activity for Sutro Biopharma
or or view top insider-buying stocks.

How do I buy shares of Sutro Biopharma?

Shares of STRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sutro Biopharma's stock price today?

One share of STRO stock can currently be purchased for approximately $21.11.

How much money does Sutro Biopharma make?

Sutro Biopharma has a market capitalization of $814.93 million and generates $42.74 million in revenue each year. The company earns $-55,740,000.00 in net income (profit) each year or ($2.43) on an earnings per share basis.

How many employees does Sutro Biopharma have?

Sutro Biopharma employs 182 workers across the globe.

What is Sutro Biopharma's official website?

The official website for Sutro Biopharma is www.sutrobio.com.

Where are Sutro Biopharma's headquarters?

Sutro Biopharma is headquartered at 310 Utah Avenue Suite 150, South San Francisco CA, 94080.

How can I contact Sutro Biopharma?

Sutro Biopharma's mailing address is 310 Utah Avenue Suite 150, South San Francisco CA, 94080. The company can be reached via phone at 650-392-8412 or via email at [email protected]


This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.